Denis Horgan
Executive Director, European Alliance for Personalised Medicine
Denis Horgan is the Executive Director of the European Alliance for Personalised Medicine (EAPM). As the Executive Director, he builds and promotes networks of collaboration between different stakeholders, involved in developing an environment for personalized medicine at the EU and national level. He supports successful policies that foster activities for a more effective, targeted and safer therapies for patients across Europe.
Prior to working with the EAPM, Denis worked with the European Cancer Patient Coalition and in the European Parliament on broad array of health issue relating to the pharmaceutical area and patient access and with international NGOs on health development projects in Afghanistan, Mexico and Palestine. He holds an LLM in International Criminal law and Masters in Management from London School of Economics.
5 blogs from the author
Posted on 02.07.2019
From here to 2024: personalized medicine for an immediate future
State of play The aim of Europe’s policies and actions in public health is to improve and protect human health, and to support the modernisation of Europe’s health systems – which the EU sees both as improving the quality of its citizens’ lives, and as a contribution to goals involving growth and jobs. While the […]
Posted on 18.09.2018
The ‘nanny state’ and the case for health literacy
For me, one of the most intriguing health policy questions of our time is how to encourage citizens to embrace healthy lifestyles. Should we tax and punish bad behaviour or empower citizens with the information they need to make their own decisions? An interesting ‘league table’ caught my eye recently. Entitled the Nanny State […]
Posted on 04.06.2018
Prevention and empowerment is the way forward in healthcare
Empowering the citizen when it comes to healthcare involves several elements, writes European Alliance for Personalised Medicine executive director Denis Horgan. It can be education regarding what is actually out there in modern medicine (not least full-genome sequencing), leading to more up-to-date knowledge on the part of the patient and the healthcare professionals (HCPs), it […]
Posted on 21.02.2017
From over-testing to over-treatment – exploring pros and cons of screening programmes
The argument has raged for some time and shows no sign of abating any time soon: screening for diseases, yes or no? Take the case of prostate cancer screening: Richard Ablin – the author of “The Great Prostate Hoax”, and the man who claims to be the first to have identified PSA (a protein created […]
How losing the battle for access to personalised medicine can mean losing the fight for survival: The story of Patricia Garcia-Prieto
“How much is my life worth?” Patricia Garcia-Prieto, professor of Organisational Behaviour at the Solvay Brussels School of Economics and Management and a mother of six and 11-year olds has asked this question multiple times. In her video, as a patient representative on a panel, she has been vocal about this thought that passed her mind every day. […]
Medtech Views
Curated by
